Lixte Biotechnology Holdings Inc. has announced the conversion of its 350,000 shares of Series A Convertible Preferred Stock into common stock. Originally issued to an investor in 2015 and 2016, these preferred shares will be converted into 72,917 shares of common stock. This move marks a significant step in the company's financial strategy as it seeks to streamline its equity structure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.